DE602006017058D1 - Verfahren zur stratifizierung von herzinsuffizienz - Google Patents

Verfahren zur stratifizierung von herzinsuffizienz

Info

Publication number
DE602006017058D1
DE602006017058D1 DE602006017058T DE602006017058T DE602006017058D1 DE 602006017058 D1 DE602006017058 D1 DE 602006017058D1 DE 602006017058 T DE602006017058 T DE 602006017058T DE 602006017058 T DE602006017058 T DE 602006017058T DE 602006017058 D1 DE602006017058 D1 DE 602006017058D1
Authority
DE
Germany
Prior art keywords
stratifying
preprobnp
devices
amount
heart failure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006017058T
Other languages
English (en)
Inventor
Ildiko Amann-Zalan
Bernhard Trauth
Otero Jose Miguel Rivera
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Roche Diagnostics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics GmbH filed Critical Roche Diagnostics GmbH
Publication of DE602006017058D1 publication Critical patent/DE602006017058D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • External Artificial Organs (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Electrotherapy Devices (AREA)
DE602006017058T 2005-05-09 2006-05-03 Verfahren zur stratifizierung von herzinsuffizienz Active DE602006017058D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05010043A EP1722232A1 (de) 2005-05-09 2005-05-09 Vorrichtungen und Verfahren zur Diagnose oder zur Früherkennung der kardialen Dysfunktion
PCT/EP2006/062031 WO2006120152A1 (en) 2005-05-09 2006-05-03 Devices and methods for diagnosing or predicting early stage cardiac dysfunctions

Publications (1)

Publication Number Publication Date
DE602006017058D1 true DE602006017058D1 (de) 2010-11-04

Family

ID=34936290

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006017058T Active DE602006017058D1 (de) 2005-05-09 2006-05-03 Verfahren zur stratifizierung von herzinsuffizienz

Country Status (10)

Country Link
US (1) US20110104813A1 (de)
EP (2) EP1722232A1 (de)
JP (1) JP4927825B2 (de)
CN (2) CN103091497A (de)
AT (1) ATE482398T1 (de)
CA (1) CA2605247A1 (de)
DE (1) DE602006017058D1 (de)
ES (1) ES2352351T3 (de)
HK (1) HK1119771A1 (de)
WO (1) WO2006120152A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1722232A1 (de) * 2005-05-09 2006-11-15 F.Hoffmann-La Roche Ag Vorrichtungen und Verfahren zur Diagnose oder zur Früherkennung der kardialen Dysfunktion
JP2010517023A (ja) * 2007-01-25 2010-05-20 エフ．ホフマン−ラ ロシュ アーゲー 心不全の評価におけるｉｇｆｂｐ−７の使用
US20120115929A1 (en) 2009-04-29 2012-05-10 Esther Elisa Johanna Maria Creemers Means And Methods For Counteracting, Preventing And/Or Determining Heart Failure, Or A Risk Of Heart Failure
EP2646822B1 (de) * 2010-11-29 2017-11-01 Alere San Diego, Inc. Verfahren zur diagnose und risikovorhersage bei herzversagen
WO2014023820A1 (en) 2012-08-09 2014-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Diagnostic of heart failure
SG11201702490PA (en) * 2014-10-10 2017-04-27 Akira Matsumori Method for detecting cardiac failure patient, method for discrimination of cardiac disease, test reagent for cardiac failure, test kit for cardiac failure, device for detecting cardiac failure, and program for detecting cardiac failure
US11193947B2 (en) 2016-06-03 2021-12-07 Cedars-Sinai Medical Center B-type natriuretic peptide proteolytic assay for cardiovascular disease risk assessment
WO2017210488A1 (en) * 2016-06-03 2017-12-07 Cedars-Sinai Medical Center B-type natriuretic peptide proteolytic assay for cardiovascular disease risk assessment
US20190257842A1 (en) * 2016-08-09 2019-08-22 Otsuka Pharmaceutical Co., Ltd. Method for assisting diagnosis of alzheimer's disease using urine biomarker
JP7414281B2 (ja) * 2017-08-08 2024-01-16 クイーンズランド ユニバーシティ オブ テクノロジー 初期心不全の診断方法
US11255844B2 (en) * 2018-03-06 2022-02-22 Fresenius Medical Care Holdings, Inc. Peritoneal dialysis systems and related methods

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744101A (en) * 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
JP2676114B2 (ja) * 1990-04-16 1997-11-12 塩野義製薬株式会社 ｈＢＮＰを認識するモノクローナル抗体および該抗体を用いるｈＢＮＰの免疫測定法
DE50015291D1 (de) * 1999-01-29 2008-09-11 Roche Diagnostics Gmbh Verfahren zum Nachweis von N-terminalem proBNP
US7632647B2 (en) * 2001-04-13 2009-12-15 Biosite Incorporated Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
AUPS169202A0 (en) * 2002-04-11 2002-05-16 Goetze, Jens Peter Neuropeptide assay
MXPA03004105A (es) * 2002-05-14 2004-10-15 Hoffmann La Roche Elaboracion de una prognosis en casos de enfermedad cardiaca usando una combinacion de marcadores.
GB0216191D0 (en) * 2002-07-11 2002-08-21 Univ Leicester Plasma urotensin in human heart failure
US8263325B2 (en) * 2002-11-15 2012-09-11 Ottawa Heart Institute Research Corporation Predicting, detecting and monitoring treatment of cardiomyopathies and myocarditis
US7109023B2 (en) * 2002-11-18 2006-09-19 Princeton Biomeditech Corporation Immunossay device for diagnosing congestive heart failure and predicting mortality in congestive heart failure patients
JP2006507510A (ja) * 2002-11-21 2006-03-02 インバーネス・メデイカル・スウイツツアーランド・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング 組織低酸素症の体液マーカー
US7092759B2 (en) * 2003-07-30 2006-08-15 Medtronic, Inc. Method of optimizing cardiac resynchronization therapy using sensor signals of septal wall motion
US7887750B2 (en) * 2004-05-05 2011-02-15 Bayer Healthcare Llc Analytical systems, devices, and cartridges therefor
EP1722232A1 (de) * 2005-05-09 2006-11-15 F.Hoffmann-La Roche Ag Vorrichtungen und Verfahren zur Diagnose oder zur Früherkennung der kardialen Dysfunktion

Also Published As

Publication number Publication date
CA2605247A1 (en) 2006-11-16
EP1880221A1 (de) 2008-01-23
ATE482398T1 (de) 2010-10-15
JP2008541078A (ja) 2008-11-20
EP1722232A1 (de) 2006-11-15
JP4927825B2 (ja) 2012-05-09
CN103091497A (zh) 2013-05-08
ES2352351T3 (es) 2011-02-17
CN101171517B (zh) 2013-10-09
EP1880221B1 (de) 2010-09-22
WO2006120152A1 (en) 2006-11-16
US20110104813A1 (en) 2011-05-05
CN101171517A (zh) 2008-04-30
HK1119771A1 (en) 2009-03-13

Similar Documents

Publication Publication Date Title
DE602006017058D1 (de) Verfahren zur stratifizierung von herzinsuffizienz
ATE511656T1 (de) Verfahren zur risikobewertung von herzeingriffen auf gdf-15-basis
ATE415662T1 (de) Bestimmung der tatsächlichen zeit, die ein prozessor bei der ausführung eines codeteiles aufwendet
DE602006016589D1 (de) Neue markierungsstrategien für den empfindlichen nachweis von analyten
ATE545032T1 (de) Diagnose von herz-kreislauf-erkrankung
ATE514950T1 (de) Verfahren zur untersuchung von sepsis bei menschen
WO2006036744A3 (en) Methods for a global assay of coagulation and fibrinolysis
DE602005024639D1 (de) Verfahren und Gerät zur Diagnose des Ermüdungsversagens von Turboladern
DE602006018035D1 (de) Verfahren und kit zur quantitativen bestimmung von small, dense ldl cholesterol
ATE478335T1 (de) Verfahren in echtzeit zur erkennung von akuten entzündungszuständen
CY1112423T1 (el) Αναλυτικη συσκευη μικροεπεξεργαστη μιας χρησης
ATE519116T1 (de) Verfahren zur normierung der konzentration von analyten in einer urinprobe
WO2004057341A3 (en) Cvd assay
ATE473448T1 (de) Verfahren zur diagnose von herz-kreislauf- krankheiten
ATE475098T1 (de) Verfahren zur messung von plasmaspiegeln von pentraxin ptx3
ATE550668T1 (de) Verfahren zur identifizierung von patienten mit erhöhtem risiko für ein unerwünschtes herz- kreislauf-ereignis
DE602005013430D1 (de) Verwendung von asc als marker für kolorektalkarzinome
ATE437182T1 (de) Diagnose von allergischen erkrankungen, atopischen erkrankungen und/oder autoimmunerkrankungen durch nachweis von autoantikörpern gegen cd28 in humanem serum
ATE472611T1 (de) Verfahren zur diagnose von sepsis durch analyse von cytokine mrna expression
ATE515574T1 (de) Verwendung von spla2-aktivität zur diagnose von herz-kreislauf-ereignissen
ATE354095T1 (de) Verfahren zur detektion von prp unter verwendung ein makrozyklischen ligand
ATE509270T1 (de) Aus blutplättchen gewonnene mikropartikel als neue diagnosemarker für eine herz-kreislauf- erkrankung
WO2009016734A1 (ja) 軽度認知機能障害の検定方法
ATE483983T1 (de) Verfahren zur diagnose von chronischem stress und verwandten erkrankungen
ATE405828T1 (de) Biomarker zur reaktionsüberwachung von cdk- hemmern in der klinik